End-of-day quote
Taipei Exchange
18:00:00 2024-05-23 EDT
|
5-day change
|
1st Jan Change
|
26.4
TWD
|
-0.56%
|
|
-0.38%
|
+3.12%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
297.2
|
356
|
350
|
450
|
786.7
|
853.3
|
Enterprise Value (EV)
1 |
407.4
|
637.2
|
609.9
|
441.4
|
620.7
|
739.7
|
P/E ratio
|
19.5
x
|
11.4
x
|
17.7
x
|
13.1
x
|
15.5
x
|
20
x
|
Yield
|
3.36%
|
2.81%
|
2.86%
|
2.78%
|
4.24%
|
3.91%
|
Capitalization / Revenue
|
0.42
x
|
0.47
x
|
0.43
x
|
0.61
x
|
0.88
x
|
1.02
x
|
EV / Revenue
|
0.58
x
|
0.83
x
|
0.75
x
|
0.6
x
|
0.7
x
|
0.89
x
|
EV / EBITDA
|
4.1
x
|
5.14
x
|
5.67
x
|
3.95
x
|
4.47
x
|
5.63
x
|
EV / FCF
|
10.1
x
|
8.01
x
|
-52.2
x
|
3.66
x
|
5.7
x
|
45.7
x
|
FCF Yield
|
9.94%
|
12.5%
|
-1.92%
|
27.3%
|
17.5%
|
2.19%
|
Price to Book
|
0.61
x
|
0.71
x
|
0.68
x
|
0.94
x
|
1.17
x
|
1.25
x
|
Nbr of stocks (in thousands)
|
25,000
|
25,000
|
25,000
|
25,000
|
33,333
|
33,333
|
Reference price
2 |
11.89
|
14.24
|
14.00
|
18.00
|
23.60
|
25.60
|
Announcement Date
|
4/30/19
|
4/22/20
|
3/31/21
|
3/16/22
|
3/9/23
|
3/7/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
703
|
763.8
|
809.7
|
739
|
889.2
|
833.2
|
EBITDA
1 |
99.29
|
123.8
|
107.6
|
111.7
|
138.8
|
131.4
|
EBIT
1 |
20.45
|
41.91
|
28.1
|
37.3
|
64.78
|
54.74
|
Operating Margin
|
2.91%
|
5.49%
|
3.47%
|
5.05%
|
7.29%
|
6.57%
|
Earnings before Tax (EBT)
1 |
19.17
|
39.3
|
25.57
|
42.79
|
64.22
|
54.53
|
Net income
1 |
15.29
|
31.38
|
19.77
|
34.4
|
50.66
|
42.74
|
Net margin
|
2.18%
|
4.11%
|
2.44%
|
4.65%
|
5.7%
|
5.13%
|
EPS
2 |
0.6100
|
1.250
|
0.7900
|
1.370
|
1.520
|
1.280
|
Free Cash Flow
1 |
40.49
|
79.6
|
-11.68
|
120.4
|
108.8
|
16.19
|
FCF margin
|
5.76%
|
10.42%
|
-1.44%
|
16.3%
|
12.24%
|
1.94%
|
FCF Conversion (EBITDA)
|
40.78%
|
64.27%
|
-
|
107.85%
|
78.38%
|
12.32%
|
FCF Conversion (Net income)
|
264.76%
|
253.66%
|
-
|
350.14%
|
214.81%
|
37.87%
|
Dividend per Share
2 |
0.4000
|
0.4000
|
0.4000
|
0.5000
|
1.000
|
1.000
|
Announcement Date
|
4/30/19
|
4/22/20
|
3/31/21
|
3/16/22
|
3/9/23
|
3/7/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
110
|
281
|
260
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
8.64
|
166
|
114
|
Leverage (Debt/EBITDA)
|
1.109
x
|
2.27
x
|
2.416
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
40.5
|
79.6
|
-11.7
|
120
|
109
|
16.2
|
ROE (net income / shareholders' equity)
|
3.18%
|
6.35%
|
3.89%
|
5.98%
|
7.51%
|
6.14%
|
ROA (Net income/ Total Assets)
|
1.44%
|
2.66%
|
1.6%
|
2.15%
|
3.59%
|
2.94%
|
Assets
1 |
1,061
|
1,178
|
1,236
|
1,602
|
1,413
|
1,454
|
Book Value Per Share
2 |
19.40
|
20.10
|
20.50
|
19.10
|
20.10
|
20.40
|
Cash Flow per Share
2 |
1.470
|
3.070
|
2.380
|
5.960
|
7.410
|
3.340
|
Capex
1 |
48.8
|
69.9
|
93.6
|
22.6
|
37.5
|
88.2
|
Capex / Sales
|
6.94%
|
9.16%
|
11.57%
|
3.06%
|
4.21%
|
10.58%
|
Announcement Date
|
4/30/19
|
4/22/20
|
3/31/21
|
3/16/22
|
3/9/23
|
3/7/24
|
|
1st Jan change
|
Capi.
|
---|
| +3.12% | 27.3M | | +38.51% | 727B | | +33.05% | 599B | | -6.23% | 354B | | +18.78% | 328B | | +1.35% | 277B | | +16.00% | 243B | | +8.09% | 205B | | -5.77% | 203B | | +6.19% | 164B |
Other Pharmaceuticals
|